OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

LONDON and NEW YORK—OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, has announced the pricing of an underwritten public offering of 10,815,000 ordinary shares at an offering price of $1.85 per ordinary share. The company said it granted the underwriter a 30-day option to purchase up to an additional 1,622,250 ordinary shares at the public offering price, less underwriting discounts and commissions.